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ABSTRACT: The biosynthetic and catabolic enzymes of the endocannabinoids tightly regulate endocannabinoid-mediated
activation of the cannabinoid CB1 receptor. Monitoring the activities of these endocannabinoid hydrolases in diﬀerent brain
regions is, therefore, key to gaining insight into spatiotemporal control of CB1 receptor-mediated physiology. We have employed
a comparative chemical proteomics approach to quantitatively map the activity proﬁle of endocannabinoid hydrolases in various
mouse brain regions at the same time. To this end, we used two diﬀerent activity-based probes: ﬂuorophosphonate-biotin (FP-
biotin), which quantiﬁes FAAH, ABHD6, and MAG-lipase activity, and MB108, which detects DAGL-α, ABHD4, ABHD6, and
ABHD12. In total, 32 serine hydrolases were evaluated in the frontal cortex, hippocampus, striatum, and cerebellum. Comparison
of endocannabinoid hydrolase activity in the four brain regions revealed that FAAH activity was highest in the hippocampus, and
MAGL activity was most pronounced in the frontal cortex, whereas DAGL-α was most active in the cerebellum. Comparison of
the activity proﬁles with a global proteomics data set revealed pronounced diﬀerences. This could indicate that post-translational
modiﬁcation of the endocannabinoid hydrolases is important to regulate their activity. Next, the eﬀect of genetic deletion of the
CB1 receptor was studied. No diﬀerence in the enzymatic activity was found in the cerebellum, striatum, frontal cortex, and
hippocampus of CB1 receptor knockout animals compared to wild type mice. Our results are in line with previous reports and
indicate that the CB1 receptor exerts no regulatory control over the basal production and degradation of endocannabinoids and
that genetic deletion of the CB1 receptor does not induce compensatory mechanisms in endocannabinoid hydrolase activity.
The endocannabinoid system consists of the cannabinoidtype 1 and 2 (CB1 and CB2) receptors, lipid messengers
termed endocannabinoids, and the hydrolytic enzymes
responsible for the biosynthesis and catabolism of these lipid
signaling molecules. 2-Arachidonoylglycerol (2-AG) and
anandamide (AEA) are the two main endocannabinoids.1
The CB1 receptor has a relatively high expression in the central
nervous system, while the CB2 receptor is more abundant in
immune cells. The CB1 receptor is among the most abundant
G-protein coupled receptors in the brain and modulates a wide
variety of signaling events, including inhibition of adenylate
cyclase activity, stimulation of ERK activation, closure of
voltage-sensitive Ca2+ channels, and opening of K+ channels.2,3
Activation of the CB1 receptor is associated with multiple
physiological processes, such as energy balance, learning and
memory, pain sensation, and neuro-inﬂammation.4−7 Unlike
classical polar neurotransmitters, which are stored in
presynaptic vesicles, 2-AG and AEA are synthesized “on-
demand” from postsynaptic membranes and act as retrograde
messengers activating presynaptic CB1 receptors, thereby
modulating neurotransmitter release. This implies that the
biosynthetic and catabolic machinery of the endocannabinoids
tightly regulates CB1 receptor activation.
8
Received: November 28, 2016
Accepted: January 20, 2017
Published: January 20, 2017
Articles
pubs.acs.org/acschemicalbiology
© 2017 American Chemical Society 852 DOI: 10.1021/acschembio.6b01052
ACS Chem. Biol. 2017, 12, 852−861
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
Several biosynthetic and catabolic endocannabinoid hydro-
lases control 2-AG and AEA levels (Figure 1). Diacylglycerol
lipase-α and -β (DAGL-α and DAGL-β) are the main enzymes
producing 2-AG. They display a tissue speciﬁc distribution and
studies using mice with congenital deletion of DAGL-α or
DAGL-β have identiﬁed DAGL-α as the primary enzyme
responsible for the biosynthesis of 2-AG in the brain.9,10 α,β-
Hydrolase-domain-containing protein 6 and 12 (ABHD6 and
ABHD12) and monoacylglycerol lipase (MAGL) inactivate 2-
AG by hydrolysis to give arachidonic acid (AA) and glycerol.
MAGL is responsible for the bulk hydrolysis of 2-AG, while
ABHD6 and ABHD12 play a more distinct role in speciﬁc cell
populations.11
The biosynthetic pathways toward AEA appear to be more
complex compared with those of 2-AG.4,6 N-arachidonoyl-
phosphatidylethanolamine (NArPE) is a key intermediate in
AEA biosynthesis. NArPE can be converted via multiple
phospholipase-dependent pathways to AEA: (a) hydrolysis by
N-acylphosphatidylethanolamine-phospholipase D (NAPE-
PLD), a metallo-β-lactamase, producing AEA and a phospha-
tidic acid in one step12 and (b) phospholipase A2 (PLA2) and
α,β-hydrolase domain-containing protein 4 (ABHD4) mediated
conversion to lyso-NArPE, followed by the action of an
unknown lysophospholipase D (PLD). Of note, lyso-NArPE
can also be converted in a two-step sequence by ABHD4 to
glycerophospho-AEA (GP-AEA) and subsequently hydrolyzed
to AEA by glycerophosphodiesterase 1 or 4 (GDE1 or
GDE4);13,14 (c) in macrophages, NArPE serves as a substrate
for an unidentiﬁed phospholipase C yielding phospho-AEA.
Hydrolysis of the phosphate group by the phosphatases,
PTPN22 or SHIP1, provides AEA.15,16 The enzymatic
inactivation of AEA is less complex and is primarily mediated
by fatty acid amide hydrolase (FAAH), which hydrolyses AEA
toward arachidonic acid and ethanolamine.4,17
The ability to monitor the activity of the diﬀerent
endocannabinoid hydrolases in various brain regions is key to
gaining insight in spatiotemporal control of CB1 receptor
activation and its physiological role. The existence of a feedback
mechanism in anterograde neurotransmitter systems through
presynaptic “autoreceptors” to control the release of the
neurotransmitters has led to the hypothesis that such an
autoregulatory mechanism could also be present in retrograde
systems, such as the endocannabinoid system.18−20 Previous
studies have investigated the eﬀect of CB1 receptor modulation
on basal endocannabinoid levels. Several studies observed
changes in AEA and/or 2-AG levels,21−25 whereas others did
not.18,26 Interestingly, Maccarrone et al. found that the
endocannabinoid system of CB1 knockout mice adapted with
age by upregulating AEA catabolism.23,24 Recently, Belluomo et
al. reported that the MAGL inhibitor JZL-195 reduced 2-AG
accumulation rates in the frontal cortex of mice lacking the CB1
receptor in glutamatergic neurons and an increase of 2-AG
accumulation under the same conditions in mice with
congenital deletion of the CB1 receptor in astrocytes.
18 In
addition, chronic elevation of 2-AG levels by genetic deletion of
MAGL or repeated administration of JZL184 led to CB1
receptor desensitization.27 These observations suggest the
existence of crosstalk between the CB1 receptor and the
endocannabinoid regulatory machinery. The pre- and post-
synaptic autoregulatory mechanisms controlling endocannabi-
noid levels are, however, poorly understood.
Changes in bulk endocannabinoid levels do not reveal which
biosynthetic or catabolic pathways are responsible for the
regulation of CB1 activity.
18,26 To this end, the activity of each
hydrolytic enzyme should be studied. Over the years, a brain
region and cell type resolved map of the molecular distribution
of endocannabinoid hydrolases has been generated by in situ
hybridization and global proteomics.28−30 These studies
provided a detailed understanding of the molecular composi-
tion of the endocannabinoid system in diﬀerent brain regions at
the mRNA and protein level. However, actual enzymatic
activity does not always correlate with mRNA and protein
levels in speciﬁc brain regions due to post-transcriptional and
post-translational processes.31,32 The activity of DAGL-α is, for
example, regulated by CaMKII-mediated phosphorylation, and
MAGL activity can be modulated by sulfenylation of speciﬁc
cysteines.33,34 Consequently, it is important to measure actual
enzyme activity in the various brain regions.
Conventional enzyme activity assays rely on radiolabeled
substrates and LC/MS-based methods.35 These assays are
expensive and time-consuming and measure the activity of one
enzyme at a time. Others and we have recently applied
comparative activity-based protein proﬁling (ABPP) and
chemoproteomics to measure serine hydrolase activity in
complex proteomes.36−39 ABPP is a technique pioneered by
Cravatt et al., which relies on active site directed chemical
probes that react, in a mechanism based fashion, with the
catalytic nucleophile of targeted enzymes. The probe
establishes a covalent bond with the catalytically active protein
and therefore reports on the abundance of active enzymes.
Activity-based probes (ABPs) generally have a ﬂuorescent or
biotin reporter group for visualization and identiﬁcation,
respectively.36 Many enzymes regulating brain endocannabi-
noid levels, including MAGL, DAGL, FAAH, ABHD4, ABHD6,
and ABHD12, belong to the serine hydrolase family; therefore
they have conserved structural features, which allow for their
targeting by speciﬁc ABPs, such as FP-TAMRA and MB064.
Here, we have used ABPP to map the relative activity of
endocannabinoid hydrolases in diﬀerent brain regions, such as
cerebellum, frontal cortex, hippocampus, and striatum. We
applied this method to investigate the existence of an
autoregulatory feedback mechanism of the CB1 receptor on
the endocannabinoid hydrolase activity by comparing the brains
of CB1 receptor knockout mice versus wild-type mice.
■ RESULTS AND DISCUSSION
Gel-based Brain Region Comparison. Previously, a β-
lactone (MB064) and ﬂuorophosphonate (FP-TAMRA) were
applied as tools to study the selectivity of the DAGL inhibitors
Figure 1. Biosynthetic and catabolic pathways of 2-AG and AEA.
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LEI104, LEI105, and DH376.38,40 The use of two ABPs extends
the range of enzymes, because the probes have orthogonal
warheads and diﬀerent recognition elements, leading to a
diﬀerent interaction proﬁle. Here, both ABPs were used to map
brain region dependent activity of endocannabinoid hydrolases
by comparative ABPP. Global assessment of serine hydrolase
activity across four diﬀerent brain regions was performed using
a gel-based assay. Membrane and soluble proteomes from
mouse cerebellum, frontal cortex, hippocampus, or striatum
were incubated with MB064 (250 nM) or FP-TAMRA (500
nM) and resolved on SDS-PAGE, and the in-gel ﬂuorescence
was analyzed. Coomassie staining was used as a protein loading
control. Using MB064, nine intense bands were identiﬁed in
the membrane fractions of the mouse brain regions, and the
identity of endocannabinoid hydrolase bands could be
established using reference inhibitors and KO tissue as
previously reported.38,40
In this manner, the bands at 120 kDa, 45 kDa, and 35 kDa
were ascribed to DAGL-α, ABHD12, and ABHD6, respectively.
FP-TAMRA labeled FAAH (64 kDa), MAGL (35 and 38 kDa),
and ABHD6 (35 kDa). All identiﬁed endocannabinoid proteins
were present in the four brain regions, but several hydrolases
demonstrated pronounced region-dependent activity (Figure
2). For example, DAGL-α activity was ∼3 times higher in the
cerebellum compared to the frontal cortex, hippocampus, and
striatum (Figure 2A,B). Interestingly, the ﬂuorescent protein
band corresponding to DAGL-α in the cerebellum was shifted
toward a higher molecular weight compared to the hippo-
campus, striatum, and frontal cortex. This could indicate that
DAGL-α carries a post-translational modiﬁcation. The activity
of ABHD12 was similar in all four brain regions, while the
activity of ABHD6 was ∼25% higher in the cerebellum
compared to the frontal cortex, hippocampus, and the striatum.
The ﬂuorophosphonate-based ABP revealed the activity of
FAAH to be ∼2 times higher in the frontal cortex and the
hippocampus compared to the cerebellum and striatum. The
signals of MAGL and ABHD6 as measured with this activity-
based probe are overlapping and could not be quantiﬁed
independently (Figure 2C).
Chemoproteomic Brain Region Comparison. To
analyze the relative activities in depth, ABPP was coupled to
high resolution mass spectrometry. This methodology enables
direct identiﬁcation of the enzymes and provides a more
accurate quantiﬁcation by avoiding band overlap and yields a
Figure 2. Gel-based mapping of brain region dependent hydrolase activity. (A) Activity-based protein proﬁling with MB064 in four mouse brain
regions. (B) Quantiﬁcation of endocannabinoid hydrolase activity as determined with MB064 (mean ± SD; n = 3). (C) Activity-based protein
proﬁling with FP-TAMRA in four mouse brain regions. (D) Quantiﬁcation of FAAH activity as measured with ABP FP-TAMRA (mean ± SD; n =
3). Statistical analysis was performed by means of two-way ANOVA with Tukey multiple comparisons test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; C
= cerebellum, F = frontal cortex, H = hippocampus, S = striatum). Integrated band intensity is corrected for protein loading (coomassie).
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broader range of hydrolases due to a higher sensitivity.
Membrane and soluble proteomes from cerebellum, hippo-
campus, frontal cortex, or striatum were separately incubated
with MB108 or FP-biotin, biotinylated versions of MB064 and
FP-TAMRA, respectively. Targeted enzymes were enriched by
avidin chromatography, followed by on-bead digestion using
Figure 3. Brain region dependent chemoproteomic mapping of relative hydrolase activity. (A) Schematic representation of the chemoproteomic
workﬂow. (B) Heat map of relative enzyme activity as measured by a ﬂuorophosphonate (FP)-based activity-based probe conjugated to a biotin
reporter tag (FP-biotin) and a β-lactone-based activity-based probe conjugated to a biotin reporter tag (MB108). Data are calculated from the mean
ratios of the comparison between cerebellum and striatum, frontal cortex and striatum, and cerebellum and hippocampus. Each comparison was
performed in three biological replicates. The relative enzyme activity in the brain region in which the serine hydrolase displayed highest activity was
set to 100%. (C) Correlation graph for enzymes detected by both MB108 and FP-biotin. (D) Endocannabinoid regulating enzymes show signiﬁcant
diﬀerence between the studied brain regions (mean ± SEM; n = 3). Statistical analysis was performed by means of two-way ANOVA with Tukey
multiple comparisons test (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001) (C = cerebellum, F = frontal cortex, H = hippocampus, S =
striatum).
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sequencing grade trypsin. Tryptic peptides from diﬀerent brain
regions were isotopically labeled by reductive dimethylation
with deuterated or nondeuterated formaldehyde. After 1:1
mixing of the diﬀerentially labeled brain regions, samples were
measured by high resolution MS/MS and analyzed using
Maxquant software (a schematic overview of the chemo-
proteomic workﬂow is given in Figure 3A).41
Using this chemoproteomic methodology, the relative
activity of 33 diﬀerent serine hydrolases was quantiﬁed in all
brain regions, including DAGL-α, FAAH, ABHD12, MAGL,
ABHD6, and ABHD4 (see Figure 3 for a heat map). Eleven
enzymes reacted with both probes. A high correlation was
found between the quantiﬁed enzymatic activities for each
probe (Pearson’s correlation of 0.86 (P < 0.0001)), indicating
that probe-independent protein activity was measured (Figure
3). The ﬂuorophosphonate-based ABP targeted 14 unique
proteins, including MAGL and FAAH, whereas the β-lactone-
based ABP MB108 targeted seven unique proteins including
ABHD4, ABHD12, and DAGL-α. ABHD4 showed an equal
activity across all brain regions, while FAAH had the highest
activity in the hippocampus and frontal cortex. The activity of
DAGL-α in the cerebellum was ∼2-fold higher compared to the
striatum, hippocampus, and frontal cortex. Interestingly, MAGL
activity was lowest in the cerebellum. The results from the
chemoproteomic analysis were in line with the gel-based ABPP
method, except for ABHD6, which is likely to be caused by
band overlap in the gel-based assay. Further detailed analysis
showed that overall relative enzymatic activities followed the
same trends as observed for the protein abundance derived
from a global proteomics data set published by Sharma et al.29
(Supporting Figure 1). However, several pronounced diﬀer-
ences were detected. These diﬀerent intensity proﬁles for
activity and protein abundance may suggest that protein activity
is regulated by post-translational modiﬁcations. For example,
the activity of ABHD12 was equally distributed over the four
brain regions, while ABHD12 abundance in the hippocampus
was twice as high as in the cerebellum, frontal cortex and
striatum. These diﬀerent proﬁles might be explained by a down
regulation of ABHD12 activity in the hippocampus. DAGL-α
activity was highest in the cerebellum, while its relative activity
in the frontal cortex was 47.2 ± 8.6%, 64.6 ± 9.0% in the
hippocampus and 36.3 ± 5.4% in the striatum. In contrast,
global proteomics data showed the highest abundance of
DAGL-α in the hippocampus, while less than 30% was found in
the cerebellum, frontal cortex, and striatum. To investigate this
apparent discrepancy, we have performed a Western blot
analysis to check the DAGL-α protein levels in the four brain
regions of our mice. We observed relatively high DAGL-α
abundance in the cerebellum (Supporting Figure 2), which
matched the relative activity as measured with our ABPP
method.
Many other serine hydrolases were detected next to the
endocannabinoid hydrolases (Figure 3). Marked diﬀerences in
activity between the brain regions were observed for some of
these enzymes. For example, acetylcholinesterase (ACHE),
which is responsible for acetylcholine hydrolysis, showed over
10-fold activity in the striatum compared to the other three
brain regions. ABHD16A, which is a phosphatidylserine lipase
producing lyso-phosphatidyl-serine,42 demonstrated ∼2-fold
increased activity in the cerebellum compared to other brain
regions. Platelet-activating factor acetylhydrolase (PLA2G7),
which cleaves the sn-2 acetyl of acetyl-glyceryl-ether-phosphor-
ylcholine, showed an approximate 3-fold higher activity in the
cerebellum compared to the other brain regions.43
Comparison of CB1
+/+ and CB1
−/− Brain Regions. Next,
the regulatory control of the CB1 receptor over basal
production and degradation of endocannabinoids was inves-
tigated. To this end, the enzymatic activity of hydrolases
involved in endocannabinoid biosynthesis and degradation in
the cerebellum, hippocampus, frontal cortex, and striatum of
CB1 receptor knockout mice was compared to their wild-type
counterparts. Fluorescent scanning of gels from ABPP
experiments using MB064 and FP-TAMRA did not reveal
any diﬀerence in labeling patterns in the brain regions (Figure
4).
To investigate in depth the eﬀect of CB1 receptor deletion on
serine hydrolase activity, the chemoproteomic assay in the four
mouse brain regions was performed. The relative activities of 36
diﬀerent hydrolases were detected and quantiﬁed (Figure 5).
No diﬀerence in the enzymatic activity of the 2-AG biosynthetic
enzyme (DAGL-α) and the 2-AG catabolic enzymes ABHD6,
ABHD12, and MAGL was observed in the cerebellum, frontal
cortex, hippocampus, or striatum. Nor were any changes
observed in ABHD4 and FAAH activities.
Figure 4. Gel based CB1+/+ vs CB1−/− comparison. Study of enzyme activity in CB1+/+ and CB1−/− mouse brain regions as measured by two activity
based probes (MB064 and TAMRA-FP, n = 3). No diﬀerence in enzyme activity between CB1−/− and CB1+/+ was observed.
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■ DISCUSSION
The enzymes responsible for endocannabinoid biosynthesis and
degradation tightly regulate endocannabinoid CB1 receptor
activation. A ﬂuorescence and chemoproteomic ABPP assay
was employed to quantify the activity of hydrolases in the
cerebellum, hippocampus, striatum, and frontal cortex to gain
more insight in the spatiotemporal control of CB1 receptor-
mediated physiology. ABPP relies on the mechanism-based
Figure 5. Comparison of enzyme activity in CB1+/+ and CB1−/− mouse brain regions. Log2 ratio of enzyme activity in CB1
−/− brain regions
compared to CB1+/+ (mean ± SD). Activity is measured by activity-based proteomics using FP-biotin (10 μM) and MB108 (10 μM). Combined
data from both activity based probes (n = 4 for each brain region). Statistical analysis by means of one-way ANOVA, each CB1 WT/KO ratio was
compared to a Log2 ratio of 0; subsequently the p values were subjected to Benjamini Hochberg correction. Setting the false discovery rate at 10%.
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formation of a covalent bond between the ABP and the
catalytic nucleophile of its target enzyme. Therefore, the
abundance of only active enzymes is monitored by ABPP. The
gel-based ﬂuorescence assay has a relatively short experimental
time (∼3h) and has the ability to retrieve information on
diﬀerences in protein migration on SDS-PAGE caused by, e.g.,
phosphorylation, glycosylation, or proteolysis. The chemo-
proteomic methodology is complementary and directly reports
on the identity and activity of a large number of enzymes in
parallel in their native environment with all post-translational
modiﬁcations in place.
Previous studies have indicated the importance of analyzing
diﬀerent brain regions when studying the endocannabinoid
system. Endocannabinoid levels have been shown to vary
between brain regions. Moreover, the CB1 receptor and the
endocannabinoid regulatory machinery do not present a
homogeneous expression across brain regions.1,26,29,44 These
variations are conﬁrmed in the comparative ABPP approach
using cerebellum, hippocampus, frontal cortex, and striatum.
Signiﬁcant diﬀerences were found in the enzyme activity of
DAGL-α, MAGL, ABHD6, and FAAH between diﬀerent brain
regions. For instance, the highest FAAH activity was observed
in the hippocampus, which is in line with previous reports
indicating that the hippocampus has the highest FAAH
expression levels, highest AEA levels, and turnover rate
compared to other brain regions.18,21,26 These observations
suggest that AEA has an important physiological role in the
hippocampus, such as providing “on demand” CB1 receptor-
dependent neuroprotection against excitotoxicity.45 Next to its
role as an endocannabinoid, AEA functions also as an
endogenous agonist of the TRPV1 ion channel.46 It could be
envisioned that FAAH not only terminates CB1 receptor
signaling but also limits TRPV1 signaling by AEA in the
hippocampus. In this respect, it would be interesting to
investigate whether TRPV1 mediates crosstalk between AEA
and 2-AG biosynthesis as was previously observed in the
striatum.47 Of note, FAAH does not only inactivate AEA but
uses a wide range of long chain fatty acid amides as substrates.
The physiological role of these endogenous signaling lipids is
poorly understood, but the hippocampus would be an excellent
brain region in which to investigate their biological role.
DAGL-α activity was ∼2 fold higher in the cerebellum
compared to the frontal cortex, striatum, and hippocampus.
The activity of MAGL in the cerebellum was only 23.3 ± 11%
of the total MAGL activity in the frontal cortex. In addition, no
relative compensatory activity of ABHD6 and ABHD12 was
observed in the cerebellum (Figure 2). Yet, 2-AG levels are not
substantially higher in the cerebellum.21,26,48 This may suggest
that 2-AG levels and CB1 receptor activity are controlled by
MAGL, rather than by 2-AG biosynthesis, or that other
catabolic pathways, such as oxidative catabolism, could play a
role in this brain region.
Comparison of the activity-based proteomics data with
protein expression values from the literature showed an overall
correlation. For several enzymes (e.g., ABHD16A, ABHD10,
ABHD12), however, the activity proﬁle did not match the
protein abundance proﬁle as reported in a global proteomics
data set.29 This may indicate that the activity of these proteins
is regulated by post-translational modiﬁcations or could result
from diﬀerences in the protein expression due to variation in
age and mouse species analyzed in the various studies (as
observed with DAGL-α).
Previous studies have investigated the eﬀect of CB1 receptor
modulation by pharmacological or genetic means on
endocannabinoid levels.18,21−26 Here, this question was
revisited, and the ABPP-methodology was employed to study
the eﬀect of genetic deletion of the CB1 receptor on
endocannabinoid hydrolase activity in various brain regions.
No signiﬁcant diﬀerences in the activity of endocannabinoid
biosynthetic and catabolic enzymes between CB1 KO and WT
brain regions were observed. These results are in line with
previous reports.26,18 Yet, it cannot be excluded that speciﬁc
CB1 receptor populations might increase production and/or
degradation while others might decrease it, leading to a lack of
change when removing all these receptor populations. In
support of this hypothesis is the observation that within the
frontal cortex the turnover of 2-AG is decreased and increased
in mutant mice lacking CB1 receptors on principal neurons
(possibly glutamatergic) and on astrocytes, respectively.18
Of note, the applied technique has several limitations. The
total enzyme activity is measured by an end point measurement
using a covalent inhibitor. Therefore, small changes in the KM
as a result of post-translational modiﬁcations are diﬃcult to
monitor by ABPP. Additionally, although the proteomics assay
is capable of detecting a wide array of hydrolases that play an
important role in regulation of endocannabinoid signaling, this
methodology is not compatible with enzymes that do not form
a covalent intermediate with their substrate, such as the β-
metallo-lactamase NAPE-PLD. Importantly, other mechanisms
that regulate endocannabinoid signaling, such as the putative
endocannabinoid transporter proteins and oxidative metabo-
lism of endocannabinoids toward eicosanoids, are not taken
into account by the ABPP-method.
In conclusion, we have employed an ABPP method that can
measure the activity of six diﬀerent enzymes with endocanna-
binoid hydrolase activity in their native setting in a single
experiment. This methodology was used to map endocanna-
binoid hydrolase activity in the cerebellum, striatum, frontal
cortex, and cerebellum. This revealed brain region speciﬁc
diﬀerences in endocannabinoid hydrolase activity. The method
was applied to study the eﬀect of genetic deletion of the CB1
receptor in these brain regions. The results indicate that the
CB1 does not exert regulatory control over the basal
production and degradation of endocannabinoids and that
genetic deletion of the CB1 receptor does not induce any
compensatory mechanism in endocannabinoid hydrolase
activity.
■ METHODS
Animals. The experiments were conducted in strict compliance
with European directives and French laws on animal experimentation
(authorization number C33 12024 to F.C. from the French Ministry of
Agriculture). The experiments were conducted on brains of male CB1
WT and KO mice that were sacriﬁced at the age of 8−9 weeks. The
mice were bred at the NeuroCentre INSERM U862.
Preparation of Mouse Tissue Proteome. The mouse brain
regions, hippocampus, striatum, cerebellum, and frontal cortex, were
slowly thawed on ice. The thawed mouse brain regions were dounce
homogenized in cold (4 °C) pH 7.2 lysis buﬀer A (20 mM HEPES at
pH 7.2, 2 mM DTT, 1 mM MgCl2, 25 U/mL Benzonase) and
incubated for 5 min on ice. The suspension was centrifuged (2500g, 3
min, 4 °C) to remove debris. The supernatant was collected and
subjected to ultracentrifugation (100.000g, 45 min, 4 °C, Beckman
Coulter, Type Ti70 rotor). This yielded the membrane fraction as a
pellet and the cytosolic fraction in the supernatant. The supernatant
was collected, and the membrane fraction was suspended in storage
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buﬀer (20 mM HEPES at pH 7.2, 2 mM DTT). The total protein
concentration was determined with Quick Start Bradford assay
(Biorad) or Qubit protein assay (Invitrogen). Membranes and
supernatant fractions were both diluted to a total protein
concentration of 0.5 mg mL−1 and were used directly or ﬂash frozen
in liquid nitrogen and stored in aliquots at −80 °C until use.
Activity-based Protein Proﬁling. Mouse hippocampus, striatum,
cerebellum, or frontal cortex (0.5 mg mL−1) were incubated with
activity-based probe MB064 (250 nM) or TAMRA-FP (500 nM) for
20 min. At room temperature, Laemlli buﬀer was added to quench the
protein activity, and the mixture was allowed to stand at room
temperature for 30 min before the samples were loaded and resolved
on SDS page gel (10% acrylamide). The gels were scanned using a
ChemiDoc MP system (Cy3 settings, 605/50 ﬁlter) and analyzed
using Image lab 4.1. After ﬂuorescent scanning, the gels were stained
with a coomassie staining solution. After destaining, the gels were
scanned, and protein loading was quantiﬁed using image lab 4.1. Gel
ﬂuorescence intensities were corrected for protein abundance (loading
control).
Proteomics. Proteomics experiments were performed in a similar
fashion to those reported previously.38 A detailed protocol is given in
the Supporting Information.
Statistical Analysis. Statistical analysis for mouse brain WT versus
CB1 knockout screen was performed. For proteins identiﬁed by both
probes, the normalized ratios from Maxquant were combined for
further analysis. Using GraphPad Prism 7.0 software, the binary
logarithm of each ratio was compared to 0 with one-way ANOVA. The
resulting p values were subjected to a Benjamini−Hochberg
correction, setting the false discovery rate at 10% (q = 0.1). Brieﬂy,
the p values of all quantiﬁable hits were ordered from lowest to
highest, and the Benjamini−Hochberg statistic was calculated as q *
(position in the list) divided by the number of tests. Subsequently, the
proteins for which the p value is smaller than the BH statistic are
controlled for an FDR of q* 10%.
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